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Strengths and limitations of this study
 ► This study shows real- world clinical practice in a 
wide range of centres and countries.
 ► To the best of our knowledge, this is the first study 
of dabigatran for secondary stroke prevention in pa-
tients treated with reperfusion therapies.
 ► The study is observational and based on a retro-
spective analysis of an ongoing database, with all 
the limitations of this type of study design.
 ► Another limitation is that we are only reporting cases 
deemed by participating clinicians to be eligible for 
oral anticoagulation for secondary prevention.
AbStrACt
background and objective The optimal timing for 
initiation of dabigatran after acute ischaemic stroke (AIS) is 
not established. We aimed to evaluate initiation timing and 
clinical outcomes of dabigatran in AIS patients with non- 
valvular atrial fibrillation (NVAF).
Design Retrospective study based on prospectively 
collected data in SITS (Safe Implementation of Treatment 
in Stroke) Thrombolysis and Thrombectomy Registry from 
July 2014 to July 2018.
Participants European NVAF patients (≥18 years) 
hospitalised after first- ever ischaemic stroke.
Setting A multinational, observational monitoring register.
Intervention Dabigatran initiation within 3 months after 
the ischaemic stroke.
Primary and secondary outcomes The primary outcome 
was time from first- ever ischaemic stroke (index event) 
to dabigatran initiation. Additional outcomes included 
physicians’ reasons for delaying dabigatran initiation 
beyond acute hospital discharge and outcomes within 3 
months of index event.
Methods We identified patients with NVAF who 
received dabigatran within 3 months of the index event. 
We performed descriptive statistics for baseline and 
demographic data and clinical outcomes after dabigatran 
initiation.
results In total, 1489 patients with NVAF received 
dabigatran after AIS treated with thrombolysis and/or 
thrombectomy. Of these, 1240 had available initiation time. 
At baseline, median age was 75 years; 53% of patients 
were women, 15% were receiving an oral anticoagulant, 
29% acetylsalicylic acid and 4% clopidogrel. Most patients 
(82%) initiated dabigatran within 14 days after the index 
event. Patients initiating earlier had lower stroke severity 
from median NIHSS 8 (IQR 6–13) if initiated within 7 days 
to NIHSS 15 (9–19) if initiated between 28 days and 3 
months. Most common reasons for delaying initiation were 
haemorrhagic transformation or intracranial haemorrhage, 
stroke severity and infarct size. Few thrombotic/
haemorrhagic events occurred within 3 months after the 
index event (20 of 926 patients, 2.2% with the available 
data).
Conclusions Our findings, together with previous 
observational studies, indicate that dabigatran initiated 
within the first days after an AIS is safe in patients 
treated with intravenous thrombolysis, endovascular 
thrombectomy or both.
trial registration number SITS Thrombolysis and 
Thrombectomy Registry (NCT03258645).
IntroDuCtIon
Cardioembolic stroke, the most severe 
ischaemic stroke subtype, related mostly to 
non- valvular atrial fibrillation, accounts for 
13%–26% of all ischaemic strokes.1 Its recur-
rence rate within the first 14 days without 
anticoagulation is around 5%.2 Anticoag-
ulation using heparin decreases the risk of 
ischaemic stroke recurrence to 3.0%, but at 
the cost of 1.8% increase risk of the absolute 
risk of intracranial bleeding.3 Meanwhile, 
the rate of ischaemic stroke recurrence may 
decrease to as low as 2.8% within 90 days 
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when a direct oral anticoagulant (DOAC) is prescribed.4 
For clinicians, the decision on when to initiate antico-
agulation after an acute ischaemic stroke (AIS) is still a 
challenge, mainly due to perceived risk of early intrace-
rebral haemorrhage.
The latest Cochrane systematic review in 2015 
concluded that early anticoagulant therapy is not associ-
ated with net short- term or long- term benefit in patients 
with AIS.5 Moreover, neither national nor international 
stroke guidelines give firm recommendations. The 
American Heart Association- American Stroke Asscia-
tion (AHA- ASA) 2018 guidelines state that starting oral 
anticoagulation (OAC) within 4–14 days after AIS is 
reasonable for most patients, and the European Society 
of Cardiology 2016 and European Heart Rhythm Associ-
ation 2018 guidelines, endorsed by the European Stroke 
Organisation, recommend starting OAC 1, 3, 6 and 12 
days, respectively, after transient ischaemic attack, minor, 
moderate and severe strokes.6–8
Clinical practice is, therefore, to delay anticoagulation 
by up to 14 days. As the risk of recurrence during this 
time is around 5%, many clinicians initiate anticoagula-
tion earlier, guided by the approximate size of the infarct 
and the absence or the presence of any haemorrhagic 
transformation.
The lower overall risk of intracranial haemorrhage 
(ICH) with DOACs compared with vitamin K antago-
nists (VKA) may facilitate earlier anticoagulation using 
DOACs in these patients.9 Recent observational studies 
indicate that the risk of symptomatic ICH in patients 
treated with DOACs within the first 5 days of ischaemic 
stroke is low.10–12 A pooled individual patient data anal-
ysis of seven observational studies concluded that DOACs 
started early after AIS were associated with reduced risk of 
poor clinical outcomes compared with VKA, mainly due 
to lower risk of ICH.13
Regarding dabigatran, patients were randomised in the 
Randomized Evaluation of Long- Term Anticoagulation 
Therapy (RE- LY) trial no sooner than 14 days after AIS.14 
More recently, a smaller trial, including 301 patients with 
Transient Ischemic Attack (TIA) or minor ischaemic 
stroke (NIHSS <9), showed that dabigatran and aspirin 
had similar safety with a non- significant trend for fewer 
early recurrent ischaemic strokes in the dabigatran 
arm.15 16
The optimal timing of anticoagulation after an AIS is 
not established, and until results of ongoing randomised 
controlled trials are published, observational studies 
are needed to provide recommendations for clinical 
practice.
The primary aim of this observational study was to eval-
uate the timing of dabigatran initiation in AIS patients 
with NVAF treated with intravenous thrombolysis (IVT), 
endovascular thrombectomy (EVT) or both. Secondary 
aims were (1) to report physicians’ reasons to delay 
OAC and (2) to evaluate clinical outcomes at 3- month 
follow- up.
MAterIAl AnD MethoDS
Patients presenting with first- ever AIS and NVAF recorded 
in the Safe Implementation of Treatment in Stroke- Atrial 
Fibrillation (SITS- AF) registry between July 2014 and July 
2018 were included.
The SITS- AF registry is a subset of the Safe Implementa-
tion of Treatment in Stroke- International Stroke Throm-
bolysis Registry (SITS-ISTR), an ongoing, prospective, 
academic- driven and multinational, register for clinical 
centres treating patients with acute stroke. The method-
ology of the SITS- ISTR, including procedures for data 
collection and management, patient identification and 
verification of source data has been described previously.17
In the present study, patients were included if they 
presented with stroke symptoms and were treated with 
intravenous alteplase (Actilyse, Boehringer Ingelheim, 
Ingelheim, Germany) within or outside license criteria, 
and/or with endovascular thrombectomy (EVT). Need 
for ethical approval or patient consent for participation 
in the SITS- ISTR varied among participating countries. 
Ethics approval and patient consent were obtained in 
countries that required this; other countries approved 
the register for conduct as an anonymised audit.
We collected baseline and demographic characteris-
tics, premorbid modified Rankin Scale (mRS), variables 
required for CHA2DS2- VASc and HAS- BLED scores, stroke 
severity as per the NIHSS, medication history, imaging 
data at admission and follow- up, time interval in days 
between index event and start of dabigatran and physi-
cians’ reasons for delaying dabigatran initiation beyond 
acute hospital discharge. Follow- up period for this study 
was 3 months, during which we collected information on 
any new clinical events, functional outcome using the mRS 
and death. All assessments of imaging studies, neurolog-
ical status and functional status were done according to 
clinical routine at centres participating in the SITS- ISTR.
outcomes
The primary outcome was the time from index event 
(first- ever ischaemic stroke) to dabigatran initiation. 
Secondary outcomes included physicians’ reasons for 
delaying dabigatran initiation beyond acute hospital 
discharge and clinical outcomes of interest within 3 
months of the index event. Clinical outcomes of interest 
include death, stroke or systemic embolism, ICH or major 
bleeding defined according to the International Society 
on Thrombosis and Hemostasis, all within 3 months after 
the index event.18 The timing of initiation was at the 
discretion of the treating physicians.
Statistical analysis
We performed descriptive statistics for baseline, imaging 
and demographic data. For continuous variables, median 
and IQR and mean and SD values were obtained. For cate-
gorical variables, we calculated percentage proportions 
by dividing the number of events by the total number of 
patients, excluding missing or unknown cases.16 Compar-
isons were made using Mann- Whitney U test and χ2 test 
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Figure 1 Flowchart of the study.
as appropriate. Pearson correlation coefficient was used 
to correlate dabigatran initiation time with continuous 
variables. A multivariable regression model, including 
potential confounders (clinically relevant variables and 
variables based on a univariate significance of p<0.05), 
was used to establish association between baseline vari-
ables and dabigatran initiation time. Because of the low 
number of events, no inferential analysis was performed. 
To calculate annualised incidence rates, we calculated the 
number of patient- years (number of included patients 
multiplied by the follow- up time in years). Incidence rates 
were expressed per 100 person- years. The 95% CIs for 
incidence rates were calculated using Fisher’s exact test.
Patient and public involvement
Patients or the public were not involved in the design, 
conduct, reporting or dissemination plans of our research.
reSultS
The dataset comprised 14 695 patients with first- ever 
AIS and NVAF, diagnosed either before the stroke or 
within 3 months after the event. Of these, 1489 patients 
received dabigatran treatment for secondary preven-
tion. The information regarding dabigatran initiation 
timing was available in 1240 patients, who were the 
study population for primary outcome (figure 1). Base-
line and demographic characteristics in aggregate are 
presented in table 1. Baseline characteristics according 
to time of dabigatran initiation are presented in online 
supplementary table I. The median age was 75 (69–82) 
years; 656 (53%) patients were women. The median 
NIHSS at admission was 10 (6–16). The median time 
from index stroke to dabigatran initiation was 8 (4–12) 
days. About 82% of patients initiated dabigatran within 
14 days after the index stroke (online supplementary 
figure 1).
Univariate analysis showed that higher NIHSS at 
baseline and higher pre- stroke mRS were associated 
with a delay of dabigatran initiation (p<0.001 and 
p<0.01, respectively). Multivariate regression analysis, 
including clinically significant variables (age, gender, 
baseline NIHSS, systolic blood pressure on admission 
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Table 1 Baseline characteristics of dabigatran patients 
included in the study
Dabigatran patients 
with available time of 
initiation (n=1240)
Age (mean, SD) (median, IQR) 75±10 (69–82)
Gender (N, %, female) 656 (52.9)
NIHSS baseline (median, IQR) 10 (6–16)
SBP (mm Hg, mean, SD) 153±23
DBP (mm Hg, mean, SD) 85±15
Glucose (mmol/dL, mean, SD) 7.3±2.3
Weight (kg, mean, SD) 78±15
Hypertension (N, %) 955 (77)
Diabetes (N, %) 216 (17.4)
Hyperlipidemia (N, %) 349 (28.1)
Previous TIA (N, %) 65 (5.3)
Current smoker (N, %) 88 (7.1)
Previous smoker (N, %) 107 (8.8)
Congestive heart failure (N, %) 134 (10.9)
Vascular disease (N, %) 149 (12)
Renal impairment (N, %) 30 (2.6)
Abnormal liver function (N, %) 16 (1.4)
Alcohol use (N, %) 37 (3.2)
History of/predisposition to 
bleeding (N, %)
30 (2.6)
Labile INR (N, %) 39 (3.5)
Previous AF (N,%) 720 (58.6)
Previous modified Rankin Scale 
(median, IQR)
0 (0–0)
















IVT (N, %) 1055 (85.1)
EVT (N, %) 68 (5.5)
IVT+EVT (N, %) 117 (9.4)
AF, atrial fibrillation; DBP, diastolic blood pressure; EVT, 
endovascular thrombectomy; INR, International Normalised Ratio; 
IVT, intravenous thrombolysis; NIHSS, National Institutes of Health 
Stroke Scale; SBP, systolic blood pressure; TIA, Transient Ischemic 
Attack.
Table 2 Distribution of physician reasons to delay 
dabigatran initiation until after discharge from acute stroke 
care
Reasons for delay N %
Severity of stroke 61 22.8
Size of infarct 52 19.4
Haemorrhagic transformation 40 14.9
Intracranial haemorrhage 8 3.0
Reason not specified 27 10.1
Patient bleeding risk factors 18 6.7
Location of infarct 14 5.2
Practical considerations 14 5.2
Intervention used to treat ischaemic stroke 8 3.0
Patient stroke risk factors 6 2.2
Recommendation from specialist 6 2.2
Altered coagulation parameters 5 1.9
Other reasons 5 1.9
Patient preference 4 1.5
Total 268 100
and glucose level at admission) showed that older age 
(p=0.02), higher diastolic blood pressure on admis-
sion (p=0.002), higher previous CHA2DS2- VASc score 
(p=0.04) and a history of/predisposition to bleeding 
(p=0.03), were independently associated with a delay of 
dabigatran initiation.
reasons for delaying anticoagulation
Regarding reasons for delaying dabigatran initiation 
beyond the period of acute hospitalisation, a total of 268 
reasons were reported in 203 patients (1 reason in 160 
patients, more than one in 43). Table 2 shows the distri-
bution of physician responses. Of all reasons given, 65.3% 
were related to the index event, the most frequent being 
stroke severity (22.8%), size of infarct (19.4%) and haem-
orrhagic transformation (14.9%).
Follow-up
In total, 926 patients had available information at 3- month 
follow- up regarding clinical events since discharge, 
resulting in a cumulative follow- up time of 231.5 patient- 
years. Of these 926 patients, the information about the 
primary outcome (timing of dabigatran initiation) was 
only available for 702 patients.
Among 926 patients, 101 experienced at least 1 event, 
with a total of 107 events reported. Of these, 20 (2.2%) 
were considered events of interest (embolism or haem-
orrhage, defined as new stroke, myocardial infarct, 
pulmonary embolism or systemic embolism, as well as 
ICH and major extracranial haemorrhage). Thirteen of 
these events were embolic/ischaemic (seven new stroke 
since discharge (3.02%/year, 95% CI 1.22 to 6.23), three 
myocardial infarction, two pulmonary embolism and one 
systemic embolism) and seven were haemorrhagic (one 
ICH (0.43%/year, 95% CI 0.01 to 2.13) and six major 
extracranial haemorrhage). There were no differences in 
the distribution of events of interest and initiation time.
The data on mRS at 3 months after the index event were 
available in 1018 patients. A total of 697 patients (68.5%) 
were functionally independent (mRS: 0–2), and 31 (3%) 
had died. The causes of death were recorded as follows: 
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Median delay (days) 8 (4–12) 5 (3–11) (dabigatran group) 3 (1.5–6) 4 (2–7) 8 (3–14)
* Mean and SD
NIHSS, National Institutes of Health Stroke Scale; NOACISP, Novel Oral Anticoagulants in Stroke Patients; RAF- NOAC, Early Recurrence 
and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin K Oral Anticoagulants; SITS, 
Safe Implementation of Treatment in Stroke.
Table 4 Comparison of our results with dabigatran- treated 






All safety events 20 (2.2%) 9 (2.4%)
Embolism 13 (1.4%) 7 (1.8%)
Stroke/TIA 7 (0.8%) 7 (1.8%)
Other thromboembolic 
events (MI, PE or SE)
6 (0.7%) 0
Major haemorrhage 7 (0.8%) 2 (0.5%)
Intracranial 
haemorrhage
1 (0.1%) 2 (0.5%)
MI, Myocardial Infarction; PE, Pulmonary Embolism; RAF- NOAC, 
Early Recurrence and Major Bleeding in Patients With Acute 
Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin 
K Oral Anticoagulants; SE, Systemic Embolism; TIA, Transient 
Ischemic Attack.
10 (32%) due to index cerebral infarction, 1 (3.2%) 
patient due to ICH, 2 (6.5%) patients due to pneumonia, 
2 (6.5%) patients due to pulmonary embolism, 6 (19.4%) 
patients due to other causes and 10 (32%) patients had 
an unknown cause.
Tables 3 and 4 show comparisons of our results with 
previously reported observational studies. Patients in our 
study were older and had a higher stroke severity. Our 
findings regarding events of interest are in line with those 
previously reported.
DISCuSSIon
This large observational study shows that dabigatran in 
clinical practice is most commonly initiated early (82% 
patients within first 14 days) after an AIS. The rate of isch-
aemic or haemorrhagic complications during the first 
3 months after early initiation of dabigatran is low. Our 
findings suggest that the safety profile of dabigatran for 
secondary stroke prevention in clinical practice is similar 
to findings in the RE- LY trial.14
We have compared our results with those in recently 
published observational studies (tables 3 and 4). At a 
median age of 76, the patients in our series were older than 
in other studies, with the exception of the Novel Oral Anti-
coagulants in Stroke Patients (NOACISP).10–12 19 Impor-
tantly, our patients had a much higher stroke severity than 
those in previous publications due to the fact that they 
received intravenous and/or endovascular reperfusion 
therapies, median NIHSS 10 in our patients versus 2–7 in 
previous observational studies.10–12 19 The higher NIHSS 
and older age likely had a major influence on our finding 
that dabigatran was initiated at median 8 days, compared 
with 2–4 days in previous studies.10 11 19 Both stroke 
severity and reperfusion treatment are associated with an 
elevated haemorrhagic risk. In spite of this, the rate of 
large parenchymal hematoma (PH2- PHr2) in our study 
was 1% compared with 2.7%–5.1% previously reported in 
IVT patients and the rate of ICH within 3 months from 
the index event was even lower, 0.1%, compared with 
5.1% at 90 days in a meta- analysis of EVT.20–22 However, 
these findings should be interpreted with caution due to 
potential selection bias, as patients with early severe symp-
tomatic bleeding after acute treatment may have died, or 
if alive, may have been too severely disabled to be consid-
ered for OAC initiation—potentially removing bleeding- 
prone patients from the treatment- eligible population.
According to the RAF- NOAC (Early Recurrence and 
Major Bleeding in Patients With Acute Ischemic Stroke 
and Atrial Fibrillation Treated With Non–Vitamin K Oral 
Anticoagulants) study, the period of DOAC initiation 
with the lowest rates of ischaemic recurrence and major 
bleeding events would be 3–14 days after the index event 
(2.1% for composite AIS, TIA, symptomatic systematic 
embolism and major bleeding).12 Although our numbers 
of events were too low for significance testing between 
periods, the period with the lowest rate of safety events 
was 3–7 days after AIS (1.7% for composite AIS, TIA, 
symptomatic systematic embolism and major bleeding). 
When comparing safety events in our study and the dabig-
atran subgroup of RAF- NOAC, the rate of the composite 
outcome is similar (2.2% vs 2.4%), but in our series the 
rates of stroke for TIA and ICH were lower.
Our study adds new data to the recent observational 
studies regarding anticoagulation after AIS. This liter-
ature together with guideline recommendations and 
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patients’ individual embolic and haemorrhagic risks 
should guide the decision on when to start OAC therapy.
We have described physicians’ reasons to delay anti-
coagulation. Previous registry studies have shown an 
underutilisation of OAC both in primary prevention and 
after AIS.23–25 Several reasons could explain this: lack of 
knowledge of current guidelines, physician’s concern 
for the risk of bleeding and clinical factors, such as poor 
functional outcome after stroke, advanced age or the risk 
of falling. In our study, reasons for the delay of dabigatran 
initiation were mostly related to the index event and its 
putative high haemorrhagic risk.26
Our study has some limitations. The main one is that it 
only includes patients treated with IVT and/or EVT. Thus, 
there is a matter of selection of cases eligible for such ther-
apies (whether treated on- label or off- label and within or 
outside guidelines). These cases are likely to have more 
severe strokes and may have a lower pre- morbid score on 
mRS and other differences, compared with an unselected 
NVAF stroke population. Another limitation is that 16% 
of patients initiating dabigatran within 3 months from the 
index event had no available information on exact initiation 
timing. A sensitivity analysis (online supplementary table 
II) comparing clinical characteristics between patients with 
and without known initiation time showed that the latter 
group had higher NIHSS and glucose levels at baseline, less 
frequent history of previous AF and more frequently had 
endovascular treatment. These differences could potentially 
have biased our results to some extent in favour of earlier 
dabigatran initiation. Moreover, we are only reporting cases 
deemed by participating clinicians to be eligible for OAC 
treatment. In four cases of events of interest, the informa-
tion about dabigatran initiation timing was not available, 
but sensitivity analysis has been performed under different 
distribution assumptions and showed no statistical signifi-
cance regarding time initiation groups.
The strengths of our study are that it shows real- world 
clinical practice in a wide range of centres and countries, 
in which the timing of OAC was not standardised across 
the study but left to the discretion of the individual physi-
cians and centres. It is also, to the best of our knowledge, 
the first study of dabigatran for secondary stroke preven-
tion in patients treated with IVT and/or EVT, a popula-
tion in which there may be even more controversy about 
when to start OAC due to a potentially elevated risk of 
haemorrhage. In addition, our data add important safety 
information on dabigatran, as the population in this study 
was not included in the pivotal dabigatran trial RE- LY 
(patients with a recent acute stroke were excluded).
Four large randomised controlled trials, OPTIMAS 
(OPtimal TIMing of Anticoagulation After Acute Isch-
aemic Stroke : a Randomised Controlled Trial) (EudraCT, 
2018-003859-38; UK), TIMING (TIMING of Oral Anti-
coagulant Therapy in Acute Ischemic Stroke With 
Atrial Fibrillation) (NCT02961348; Sweden), START 
(Optimal Delay Time to Initiate Anticoagulation After 
Ischemic Stroke in Atrial Fibrillation) (NCT03021928; 
USA) and ELAN (Early versus Late initiation of direct 
oral Anticoagulants in post- ischaemic stroke patients 
with atrial fibrillation) (NCT03148457; Switzerland) are 
investigating the benefit of early DOAC administration 
in patients with AF- related ischaemic stroke. The results 
of these trials are expected in the coming years; in the 
meantime, clinicians have to rely on data from observa-
tional studies.
ConCluSIonS
Our findings, together with previous observational studies, 
suggest that dabigatran initiated within the first days after 
AIS is safe in patients treated with IVT, EVT or both.
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